Andrew Feinberg

Andrew Feinberg
Name	Andrew Feinberg
Birth date	1952
Birth place	New York City
Fields	Genetics, Epigenetics, Cancer research
Institutions	Johns Hopkins University School of Medicine, Dana–Farber Cancer Institute, National Institutes of Health
Alma mater	Brown University, Harvard Medical School
Known for	DNA methylation, epigenetic alterations in cancer, discovery of CpG island methylation
Awards	E. Mead Johnson Award, Fellow of the American Association for the Advancement of Science

Andrew Feinberg

Andrew Feinberg is an American biologist and physician-scientist renowned for pioneering work in epigenetics, particularly DNA methylation and its role in cancer. His research links epigenetic alterations to developmental disorders, tumorigenesis, and environmental exposures, influencing fields spanning molecular biology, genomics, and public health. Feinberg's career includes leadership roles at major research centers and significant contributions to translational and basic science literature.

Early life and education

Feinberg was born in New York City and completed undergraduate studies at Brown University before attending Harvard Medical School for his MD. During training he interacted with figures from institutions such as McGill University, Massachusetts General Hospital, Johns Hopkins University School of Medicine, and mentors connected to National Institutes of Health programs. His early exposure to laboratories associated with Howard Hughes Medical Institute investigators and conferences like the Cold Spring Harbor Laboratory meetings shaped an interdisciplinary focus bridging molecular biology and clinical investigation.

Research and contributions

Feinberg's work established key paradigms in epigenetics, especially the discovery and characterization of abnormal DNA methylation patterns in cancer cells, including hypermethylation of CpG islands and global hypomethylation leading to genomic instability. He and colleagues demonstrated links between epigenetic dysregulation and oncogenes/tumor suppressors studied in BRCA1, p53, and MLH1 research streams, connecting epigenetic change to pathways examined by investigators at Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. His lab developed methods that complemented genomic technologies from Broad Institute and sequencing advances by Illumina and Pacific Biosciences, enabling genome-wide mapping of methylation landscapes alongside efforts by the Human Genome Project and the ENCODE consortium.

Beyond cancer, Feinberg's research addressed epigenetic regulation in developmental biology contexts influenced by studies from Stanford University, University of California, San Francisco, and Cold Spring Harbor Laboratory. He contributed to understanding imprinting phenomena paralleling work on Igf2 and H19, and to environmental epigenetics linking exposure studies by Environmental Protection Agency-associated researchers and epidemiologists at Johns Hopkins Bloomberg School of Public Health. Feinberg proposed models for stochastic epigenetic variation that influenced theoretical frameworks used by groups at Harvard University and Yale University.

His collaborative projects integrated epigenomic data with cancer biology initiatives such as The Cancer Genome Atlas and drew comparisons to epigenetic aging studies led by teams at Stanford University and University of California, Los Angeles. Feinberg's conceptualization of epigenetic plasticity and cancer risk informed translational efforts at institutions like Sloan Kettering Institute and spurred therapeutic investigations involving epigenetic drugs evaluated at Food and Drug Administration-regulated clinical trials.

Career and positions

Feinberg held faculty positions at Johns Hopkins University School of Medicine, where he served in roles within departments connected to Oncology, Genetics, and Epidemiology programs. He directed research programs that interfaced with centers such as Sidney Kimmel Comprehensive Cancer Center and collaborated with investigators from Dana–Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Brigham and Women's Hospital. Feinberg also engaged in national research leadership through ties to the National Institutes of Health and advisory collaborations with the National Cancer Institute and international consortia, participating in symposia at European Molecular Biology Laboratory and policy discussions with World Health Organization-affiliated panels.

Awards and honors

Feinberg's honors include election as a fellow of the American Association for the Advancement of Science and recognition through awards such as the E. Mead Johnson Award and prizes conferred by professional societies including the American Association for Cancer Research and the American Society of Human Genetics. He has delivered named lectures at institutions like Cold Spring Harbor Laboratory, McGill University, and Harvard Medical School, and received honorifics from organizations such as Society for Developmental Biology and regional academies affiliated with National Academies of Sciences, Engineering, and Medicine.

Selected publications and impact

Feinberg authored and coauthored influential papers on DNA methylation, epigenetic deregulation in cancer, and stochastic epigenetic variation published in journals where related work by peers at Nature, Science, Cell, Proceedings of the National Academy of Sciences, and Nature Genetics commonly appears. Representative topics include genome-wide methylation profiling, CpG island hypermethylation, and epigenetic contributions to tumor heterogeneity paralleling investigations at Broad Institute and The Cancer Genome Atlas consortium. His studies influenced methodological advances in bisulfite sequencing and methylation arrays developed alongside technologies from Illumina and analytic frameworks used in projects at ENCODE and the International Human Epigenome Consortium.

Feinberg's scholarship has shaped clinical translation efforts addressing epigenetic biomarkers for diagnosis and prognosis in malignancies studied at Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, and MD Anderson Cancer Center, and informed trials of epigenetic therapies overseen by Food and Drug Administration regulatory pathways. His conceptual contributions continue to be cited in contemporary work by researchers at Stanford University, Harvard University, Yale University, University of California, San Francisco, and other leading centers advancing epigenetics and cancer biology.

Category:Epigeneticists Category:American medical researchers